AstraZeneca awaiting Seroquel XR approval

Share this article:
AstraZeneca hopes the approval of a once daily version of its blockbuster schizophrenia drug Seroquel can break its streak of bad product news. The FDA is scheduled to make a decision on Seroquel XR on May 17. Many analysts believe the agency’s ruling on the drug could be a positive one. Seroquel XR’s approval could offer the company a chance to show it can still deliver, following recent failures of new drugs to treat stroke and heart disease, which came on the heels of earlier setbacks. “We believe these things can have a significant impact on our business, CEO David Brennan told Reuters in an interview in late April. “Our life cycle management programs have been excellent…we’ve done well in showing we can add incremental value to existing products.” Seroquel had sales of $3.4 billion last year and was AstraZeneca’s second biggest seller. The original immediate formulation of the drug, however, faces patent threats, with a case potentially coming to court next year in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...